Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 796

1.

Graft-versus-host disease after allogeneic hematopoietic stem cell transplantation induces a CD8+ T cell-mediated graft-versus-tumor effect that is independent of the recognition of alloantigenic tumor targets.

Stelljes M, Strothotte R, Pauels HG, Poremba C, Milse M, Specht C, Albring J, Bisping G, Scheffold C, Kammertoens T, Oelmann E, Silling G, Berdel WE, Kienast J.

Blood. 2004 Aug 15;104(4):1210-6. Epub 2004 Apr 15.

2.

Differential requirement for a cellular type-1 immune response in tumor-associated versus alloantigen-targeted GvT effects.

Stelljes M, Specht C, Albring J, Volkmann S, Schlösser V, Pauels HG, Poremba C, Bisping G, Opitz C, Scheffold C, Silling G, Kiehl M, Berdel WE, Kienast J.

Transplantation. 2007 Feb 15;83(3):314-22.

PMID:
17297406
3.

Allogeneic MHC gene transfer enhances antitumor activity of allogeneic hematopoietic stem cell transplantation without exacerbating graft-versus-host disease.

Ohashi M, Kobayashi A, Hara H, Miura Y, Yoshida K, Kushida M, Ikarashi Y, Mandai M, Kitajima M, Yoshida T, Aoki K.

Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2208-15.

5.

Graft-vs.-lymphoma effect in an allogeneic hematopoietic stem cell transplantation model.

Ito M, Shizuru JA.

Biol Blood Marrow Transplant. 1999;5(6):357-68.

6.

Engineering hematopoietic grafts: purified allogeneic hematopoietic stem cells plus expanded CD8+ NK-T cells in the treatment of lymphoma.

Verneris MR, Ito M, Baker J, Arshi A, Negrin RS, Shizuru JA.

Biol Blood Marrow Transplant. 2001;7(10):532-42.

PMID:
11760085
8.
10.

Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets.

Johnson BD, Becker EE, Truitt RL.

Biol Blood Marrow Transplant. 1999;5(3):123-32.

11.

A CD8 DE loop peptide analog prevents graft-versus-host disease in a multiple minor histocompatibility antigen-mismatched bone marrow transplantation model.

Choksi S, Kim JC, Whitaker-Menezes D, Murphy GF, Friedman TM, Korngold R.

Biol Blood Marrow Transplant. 2004 Oct;10(10):669-80.

12.

Intervention of MAdCAM-1 or fractalkine alleviates graft-versus-host reaction associated intestinal injury while preserving graft-versus-tumor effects.

Ueha S, Murai M, Yoneyama H, Kitabatake M, Imai T, Shimaoka T, Yonehara S, Ishikawa S, Matsushima K.

J Leukoc Biol. 2007 Jan;81(1):176-85. Epub 2006 Oct 19.

PMID:
17053165
13.

Alloantigen recognition is critical for CD8 T cell-mediated graft anti-tumor activity against murine BCL1 lymphoma after myeloablative bone marrow transplantation.

Pillai A, Teo P, George T, Mukhopadhyay A, Dejbakhsh-Jones S, Strober S.

Bone Marrow Transplant. 2007 Sep;40(5):487-97. Epub 2007 Jul 2.

PMID:
17603512
15.

The graft versus leukemia response after allogeneic hematopoietic stem cell transplantation.

Riddell SR, Berger C, Murata M, Randolph S, Warren EH.

Blood Rev. 2003 Sep;17(3):153-62. Review.

PMID:
12818225
16.

Allogeneic versus syngeneic killer splenocytes as effector cells for the induction of graft-versus-tumor effect.

Morecki S, Yacovlev E, Gelfand Y, Vilensky A, Slavin S.

Biol Blood Marrow Transplant. 2004 Jan;10(1):40-8.

17.

CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation.

Edinger M, Hoffmann P, Ermann J, Drago K, Fathman CG, Strober S, Negrin RS.

Nat Med. 2003 Sep;9(9):1144-50. Epub 2003 Aug 17.

PMID:
12925844
18.
20.

Supplemental Content

Support Center